Market News AIOpen the app

AKTX stock news · Akari Therapeutics

Stories about Akari Therapeutics (AKTX) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for AKTX

Follow Akari Therapeutics (AKTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AKTX
Free on the App Store and Google Play, or on the web.
  1. Oct 19, 2026, 8:14 AM ET · Market

    12 health care stocks are changing a lot before the market opens on Monday.

    Neutral

    Akari Therapeutics shares rose about 13% before trading began. The story gives no reason or company news, so it does not change the company's business outlook.

  2. Oct 14, 2026, 5:18 PM ET · Market

    12 health care stocks changed a lot in prices after the market closed on Wednesday.

    Neutral

    Akari Therapeutics shares rose 9.64% to $7.96 after hours, but the report gives no company news, so the business view is unchanged.

  3. Oct 1, 2026, 4:49 PM ET · Market

    Akari Therapeutics Plc has new directors and officers, plus changes to pay for some leaders (AKTX).

    Bad for AKTX

    Akari raised its CEO's pay and added stock awards, increasing company costs and possible share issuance. The filing reports no business gain to balance those added costs.

  4. Aug 18, 2026, 11:48 AM ET · Market

    Mid-2027 set by Akari for initiating human trials of its differentiated cancer treatment.

    Neutral

    Akari Therapeutics has announced promising preclinical results for its cancer therapy AKTX-101, which demonstrates significant efficacy against urothelial carcinoma, particularly in cases where existing treatments have failed. The company is targeting a Phase 1 clinical trial by mid-2027, which could position it favorably in the oncology market.